Schizophrenia often develops between the ages of 18 and 35, which is a critical life period for studying and for making career and professional decisions.

Stock photo. Posed by model.

As a result, most of these patients do not have the qualifications for jobs requiring professional training. Psychotherapy and psychosocial interventions are aimed at helping patients to overcome psychological, social and workplace obstacles.

These therapies can help patients with milder symptoms, or those with appropriately controlled psychotic symptoms.

The degree to which mental abilities, also known as “cognitive functions”, such as concentration, memory, thinking, planning and problem-solving are affected, have a significant impact on the chances of patients to continue their studies or to get and maintain a job.

With the new antipsychotic drugs, symptoms can be treated to an extent that schizophrenia patients will be able to continue their studies or get a job. We know many people who are successful and have a full and happy life despite their disease.

  • References

    1. APA Clinical Guidelines. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia. 2004
    2. Falkai P et al. World J Biol Psychiatry 2005; 6: 132-191.
    3. Kendler KS et al. Arch Gen Psychiatry 1996; 53: 1022-1031.
    4. World Health Organization. The World Health Report: 2001: Mental health: new understanding, new hope.
    5. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th Edition Text Revision (DSM-IV-TR). Arlington: American Psychiatric Publishing Inc. 2000.
    6. Lieberman JA et al. J Clin Psychiatry 1996; 57(suppl 9): 5-9.
    7. Breier A et al. Am J Psychiatry 1994; 151: 20-26.
    8. Robinson DG et al. Am J Psychiatry 1999; 156: 544-549.
    9. National Institute for Clinical Excellence. National Clinical Practice Guidelines Number 82.
    10. Howard R et al. Am J Psychiatry 2000; 157: 172-178.
    11. Angermeyer MC et al. Schizophr Bull 1990; 16: 293-307.
    12. Murray RM and Fearon P. J Psychiatr Res 1999; 33: 497-499.
    13. Lang UE et al. Cell Physiol Biochem 2007; 20: 687-702.
    14. Harrigan SM et al. Psychol Med 2003; 33: 97-110.
    15. Bottlender R et al. Schizophr Res 2003; 62: 37-44.
    16. Lynn Starr h. et al: Comparison of long-acting and oral antipsychotic treatment effects in patients with schizophrenia, comorbid substance abuse, and a history of recent incarceration: An exploratory analysis of the PRIDE study; Schizophr Res. 2018 Apr;194:39-46. doi: 10.1016/j.schres.2017.05.005. Epub 2017 Jun 7
    17. Awad AG et al. Pharmacoeconomics 2008; 26: 149-162.
    18. Keith SJ et al. Psychiatr Serv 2004; 55: 997-1005.
    19. Lieberman JA et al. Pharmacol Rev 2008; 60: 358-403.
    20. Tandon R et al. Psychoneuroendocrinology 2003; 28(suppl 1): 9-26.
    21. Wyatt RJ. Schizophr Bull 1991; 17: 325–351
    22. Robinson DG et al. Arch Gen Psychiatry 1999; 56: 241-247.
    23. Weiden PJ et al. Psychiatr Serv 2004; 55: 886-891.
    24. Koen L et al. Psychosomatics 2007; 48: 128-134.
    25. Novick D et al. Psychiatry Res 2010; 176: 109-113.
    26. Kozma CM et al. Changes in schizophrenia-related hospitalization and ER use among patients receiving paliperidone palmitate. Current Medical Research and Opinion. 2011.27;1603-1611

show more